SMALL CELL LUNG CANCER SYMPTOMS

To explore TNM stage and quantitative parameters (SUVmean, SUVmax, MTV, TLG) in small cell lung cancer patients who underwent 18F-FDG PET/CT before initial treatment. Subjects and methods: Retrospective analysis in 32 patients diagnosed with small cell lung cancer based on pathological results at th[r]

Methods
Patients
Between May 2005 and September 2006, 94 consecutive locally advanced NSCLC patients were treated with con- current chemotherapy and IMRT in the Department of Radiation Oncology at the Peking University School of Oncology, Beijing Cancer Hospital & Institute. Pa[r]

In recent years, systemic chemotherapy and molecular targeted therapy have become standard firstline treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

including lung cancer [20]. We report that AURKA expression/activity in lung cancer cell lines does not reg- ulate the transcriptional level of E-Cadherin . This data suggest that AURKA expression/activity was not directly involved in lung cancer ep[r]

Identifying and tracking somatic mutations in cell-free DNA (cfDNA) by next-generation sequencing (NGS) has the potential to transform the clinical management of subjects with advanced non-small cell lung cancer (NSCLC).

Non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) need to be approached carefully given the high incidence of pulmonary toxicity. Pemetrexed (PEM) is the key drug for the treatment of NSCLC.

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: A subgroup analysis of a randomized phase III trial.

Non–small-cell lung cancer (NSCLC) has been reported to develop in patients with interstitial pneumonia (IP); however, clinical, radiological, and pathological features remain to be elucidated.

Lung cancer is the most important cause of cancer-related deaths worldwide and the overall survival of patients with non-small cell lung cancer has not improved.

Mammalian target of rapamycin (mTOR) inhibitors have anti-tumor effects against renal cell carcinoma, pancreatic neuroendocrine cancer and breast cancer. In this study, we analyzed the antitumor effects of mTOR inhibitors in small cell lung cancer (SCLC) cells and sought to clarify the mechanism of[r]

Non - small cell lung cancer (NSCLC) is the largest subgroup of lung cancers, responsible for about 80% of all lung cancers. Targeted cancer therapy has opened a new window into treatment of non - small cell lung cancer. This therapy is very effective for patients who have EGFR (Epidermal growth fac[r]

Fibroblast growth factor receptor 1 (FGFR1) is correlated closely with the occurrence and development of lung cancer. FGFR1 kinase inhibitors have exhibited significant therapeutic effects against non-small-cell lung cancer. Recently, non-ATP competitive FGFR1 inhibitors have attracted extensive att[r]

N-myc downstream regulated gene 1 (NDRG1) plays a variety of roles in human cancers. Our previous studies showed that NDRG1 expression is elevated in non-small cell lung cancer and contributes to cancer growth. However, its function in apoptosis and chemoresistance in malignant tumors, including lun[r]

Lung cancer is one of the leading causes of cancer death worldwide. Even with complete resection, the prognosis of early-stage non-small cell lung cancer is poor due to local and distant recurrence, and it remains unclear which biomarkers are clinically useful for predicting recurrence or for determ[r]

Non-small cell lung cancer (NSCLC) has led to the highest cancer-related mortality for decades. To enhance the efficiency of early diagnosis and therapy, more efforts are urgently needed to reveal the origins of NSCLC.

Targeted treatment with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) is superior to systemic chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR gene mutations.

these patients. However, all of the patients with CI in our study had a sudden onset of severe neurological symptoms such as paralysis, dysarthria, and disturbance of consciousness. Therefore, lacunar infarction could not be an etiology of the CI in these patients. In our study, 10 patients[r]

Cytotoxicity of these compounds was evaluated against human non-small cell lung carcinoma NCI-H460, MCF-7 breast cancer, HeLa cervical cancer and normal mouse fibro-blast cells NIH-3 T3.[r]

Immune checkpoint blockade is developed as standard treatment for non-small cell lung cancer. However immune-related adverse events (irAE) have still unknown complications. Here, we report a patient with lung squamous cell carcinoma who developed neuromyelitis optica spectrum disorder with nivolumab[r]

Malignant pleural effusion (MPE) is a common complication of advanced lung cancer. Research has shown that secreted phosphoprotein-1 (SPP1) is essential in MPE associated with lung cancer. This retrospective study was performed to evaluate the prognostic significance of SPP1 in the MPE of patients w[r]